Having trouble viewing this email? View as Webpage
Breakthroughs, the newsletter of the Feinberg School of Medicine Research Office

NOVEMBER 2024 NEWSLETTER

The newsletter of the Feinberg School of Medicine Research Office

Accelerating Discoveries in Immunobiology Through Collaboration

Just two years out from its launch, the Center for Human Immunobiology (CHI) has quickly become a bustling hub for collaborative efforts to understand the molecular mechanisms of the immune system and translate discoveries into innovative cures for immune-regulated diseases.

Read this feature story

Celebrating 100 Years of The Journal of Clinical Investigation

Investigators from Northwestern University Feinberg School of Medicine and other academic and research institutions celebrated the 100-year anniversary of The Journal of Clinical Investigation during a day-long symposium in the Hughes Auditorium on October 18.

Read the full story

Faculty Profile

Harnessing the Immune System to Treat Central Nervous System Tumors

Catalina Lee-Chang, PhD, is an assistant professor of Neurological Surgery. Her lab is focused on elucidating fundamental aspects of the immunology of central nervous system tumors and developing novel immunotherapy strategies to tackle deadly and incurable tumors such as glioblastoma.

Read more about her research

${image.getChild('description').value}

Staff Profile

Collaborating to Enhance Departmental Research

Sara Beddow is a lab manager in the Department of Microbiology-Immunology and the MIMFlow Core Manager. She helps to advance research while also fostering community among lab managers through the Northwestern Lab Manager Group which she founded.

Read more about her work

${image.getChild('description').value}

Student Profile

Understanding Mechanisms to Combat Antibiotic-resistant Infections

Szu-Yu Kuan is a PhD student in the Driskill Graduate Program (DGP). In the laboratory of Mee-Ngan F Yap, PhD, associate professor of Microbiology-Immunology, Kuan studies bacterial pathogenesis, bacterial physiology and ribosomes.

Learn more about her research

${image.getChild('description').value}

Campus Events

Fri
Dec 06

"Adolescent experience and a putative sensitive period for learning and decision making in mice" | Linda Wilbrecht, Ph.D

Chicago - 12:00 PM - 1:00 PM

Fri
Dec 06

Friday Noon Research Conference - Carla Davis, MD (Howard University)

Chicago - 12:00 PM - 1:00 PM

Fri
Dec 06

Global Health Day

Chicago - 12:00 PM - 5:00 PM

Fri
Dec 06

Northwestern Medical Orchestra Fall Concert

Chicago - 7:30 PM - 8:30 PM

Research in the News

Chicago Magazine, October 29
The New Science of Aging Backward
Douglas Vaughan, MD, and John Wilkins, MD, were featured. 

WBEZ, October 26
Can Prison Cause Dementia? New Northwestern Study Explores How Incarceration Impacts Health
Linda Teplin, PhD, was featured.

New York Times, October 23
What Drugmakers Did Not Tell Volunteers in Alzheimer’s Trials
Rudolph J. Castellani, MD, was featured.

Check out More Media Coverage

NUCATS Corner

Leadership and Management Strategies for Clinical Investigators

Led by Kellogg faculty in an interactive classroom setting, Leadership and Management Strategies for Clinical Investigators is a highly successful collaboration between Kellogg and the NUCATS Institute held May 12-15, 2025. Participants in the four-day course are exposed to practical and effective approaches to topics including organizational culture, strategic time management, feedback and persuasion strategies, and diversifying funding sources.

Learn more about the program

${image.getChild('description').value}

Sponsored Research

Understanding Multilevel Predictors Affecting Family Formation Among Sexual and Gender Minority CouplesĀ 

  • PI: Cindy Veldhuis, PhD, assistant professor of Medical Social Sciences in the Divisions of Determinants of Health and Outcome and Measurement Science, and of Obstetrics and Gynecology 

  • Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Read more about this project

${image.getChild('description').value}

Sponsored Research

Personality Prediction of Dementia Risk and Progression

  • PI: Daniel Mroczek, PhD, chief of Determinants of Health in the Department of Medical Social Sciences and professor of Medical Social Sciences (Determinants of Health)  
  • Sponsor: National Institute on Aging

Read more about this project

${image.getChild('description').value}

Breakthroughs Podcast

Emerging Drug Targets in Parkinson's Disease with Joe Mazzulli, PhD

Nearly one million people in the US are living with Parkinson's disease, a condition for which there is still no known cause or cure. Joseph Mazzulli, PhD, has led two recent studies published in Neuron and Nature Communications uncovering previously unknown cellular mechanisms driving the disease. These studies highlight the potential for new therapeutic targets, including restoring neuronal function for patients with Parkinson's and other neurodegenerative diseases.

Listen to the podcast episode

${image.getChild('description').value}

New Faculty

Steven P. Cohen, MD

Cohen recently joined Feinberg in July 2024 as Edmond I Eger Professor of Anesthesiology and vice chair of Pain Medicine with joint appointments in Physical Medicine and Rehabilitation, Neurology, Psychiatry and Neurological Surgery. Cohen has been active in pain research, having published over 450 peer-reviewed articles and book chapters in the past 20 years in some of the top medical journals and texts. His work includes the development of an FDA-approved denervation technique for treating sacroiliac joint pain (radiofrequency ablation), helping set up and gather data on the first pain clinic in a war zone, and inventing the IV ketamine test, serving as the senior investigator on the congressionally-mandated study evaluating compounded topical creams for chronic pain and much more.  

Cohen was previously professor of Anesthesiology and Critical Care Medicine, Neurology, Physical Medicine and Rehabilitation and Psychiatry and Behavioral Sciences at the Johns Hopkins School of Medicine and the director of the Blaustein Pain Treatment Center at Johns Hopkins. He is a retired colonel in the U.S. Army, recently chaired the largest medical conference in Ukraine since the war with Russia, and continues to serve as director of Pain Research at Walter Reed National Military Medical Center with joint appointments at the Uniformed Services University of the Health Sciences. 

Read more about Cohen

${image.getChild('description').value}

Galter Library

Understanding the Impact of Data

As the scholarly community places more value on data sharing, datasets are increasingly recognized as "first-class research outputs." A well-constructed, discoverable and connected dataset can play a significant role in subsequent work – serving as trusted benchmarks, inspiring new studies or signaling knowledge translation. 

Read the full article

${image.getChild('description').value}

High Impact Research

Arseni D, Nonaka T, Jacobsen MH, Murzin AG, Cracco L, Peak-Chew SY, Garringer HJ, Kawakami I, Suzuki H, Onaya M, Saito Y, Murayama S, Geula C, Vidal R, Newell KL, Mesulam M, Ghetti B, Hasegawa M, Ryskeldi-Falcon B. Heteromeric amyloid filaments of ANXA11 and TDP-43 in FTLD-TDP type C. Nature. October 2024; 634(8034):662-668.

Asadollahi E, Trevisiol A, Saab AS, Looser ZJ, Dibaj P, Ebrahimi R, Kusch K, Ruhwedel T, Möbius W, Jahn O, Lee JY, Don AS, Khalil MA, Hiller K, Baes M, Weber B, Abel ED, Ballabio A, Popko B, Kassmann CM, Ehrenreich H, Hirrlinger J, Nave KA. Oligodendroglial fatty acid metabolism as a central nervous system energy reserve. Nature Neuroscience. October 2024; 27(10):1934-1944.

Carrico AW, Ryan DTBerona JDominguez BSSchrock JMMcDade TWNewcomb MD'Aquila RTMustanski BHIV, inflammation, and initiation of methamphetamine use in sexual and gender minorities assigned male at birthProceedings of the National Academy of Sciences of the United States of America. October 2024; 121(41):e2407046121-e2407046121.

Ciatti JLVázquez-Guardado A, Brings VE, Park J, Ruyle B, Ober RAMcLuckie AJ, Talcott MR, Carter EABurrell ARSponenburg RATrueb J, Gupta P, Kim JAvila RSeong M, Slivicki RA, Kaplan MAVillalpando-Hernandez B, Massaly N, Montana MC, Pet M, Huang Y, Morón JA, Gereau RW, Rogers JAAn autonomous implantable device for the prevention of death from opioid overdoseScience Advances. October 2024; 10(43):eadr3567-eadr3567.

Review More Publications

Featured Core

Stem Cell Core Facility

The mission of the Stem Cell Core Facility is to enable scientists at Northwestern to conduct stem cell research, particularly with induced pluripotent stem cells (iPSCs). Patient-specific iPSCs offer unprecedented opportunities to study human developmental processes and disease, using human stem cell-derived somatic cells under each person’s unique genetic constellation. They also represent a unique and very important source of cells for cell replacement therapy.

The facility offers reprogramming of primary cells, including fibroblasts and peripheral blood mononuclear cells (PBMCs). We offer a number of scientific services, including training, project consultation, cell banking and access to our facility.

Services Provided

  • Generation of human iPSCs
  • Hands-on training and workshops teaching basic methods of iPSC culturing techniques
  • Use of our facility to culture and expand your stem cells
  • Cell banking and distribution
  • Consultation and support for stem cell projects
  • Gene editing of iPSCs using CRISPR/Cas9 system

Learn more about the Stem Cell Core

NIH News

Using Artificial Intelligence and Other Digital Technologies to Enhance Grant Management Operations

NIH reviewed over 75,000 applications in fiscal year 2023. One way NIH referral staff identify potential study sections to assign these many applications to is using the AI-based Automated Referral Tool. It is a useful tool to assist NIH receipt and referral staff when making decisions about the referral of applications to the appropriate review branches. NIH is carefully exploring how AI and other related technologies may make NIH’s grant operations more robust, innovative and flexible. NIH will continue testing and refining these analytical tools’ accuracy to help improve grants management operations, save time and enhance stewardship of financial resources.

Reaffirming NIH’s Commitment to Scientific Integrity

The Final NIH Scientific Integrity Policy is now available. The final policy incorporates and is responsive to the principles and directives of the Presidential Memorandum on Restoring Trust in Government Through Scientific Integrity and Evidence-Based PolicymakingProtecting the Integrity of Government Science and A Framework for Federal Scientific Integrity Policy and PracticeThe end goal of these efforts was to institutionalize a culture of scientific integrity across the federal government by requiring that agencies either develop or update their existing policies. The areas NIH sought to strengthen their existing system are articulated in the final policy and include:

  • Defining the term “scientific integrity” for consistent use across the U.S. Government
  • Establishing the new positions of NIH Chief Scientist and NIH Scientific Integrity Official and defining the roles and responsibilities of these positions
  • Establishing the NIH Scientific Integrity Council to coordinate scientific integrity activities across the Agency
  • Adding additional protections against inappropriate political interference

Read the Latest from NIH

Funding Opportunities

Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 Clinical Trial Not Allowed)

  • Sponsor: NIH, National Cancer Institute (NCI)
  • Deadline: February 5
  • Upper amount: Application budgets are not limited but needed to reflect the actual needs of the proposed project

Innovative Pilot Mental Health Services Research Not Involving Clinical Trials (R34 Clinical Trial Not Allowed)

  • Sponsor: NIH, National Institute of Mental Health (NIMH)
  • Deadline: February 16
  • Upper amount: Direct costs are limited to $450,000 over the three-year R34 project period, with no more than $225,000 in direct costs allowed in any one year

Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial Optional)

  • Sponsor: NIH, National Institute on Drug Abuse (NIDA)
  • Deadline: March 20
  • Upper amount: Direct costs are limited to $450,000 over the three-year R34 project period, with no more than $225,000 in direct costs allowed in a single year

Thank You For Reading

We welcome your feedback. Please share it with us via email.

Breakthroughs, the newsletter of the Feinberg School of Medicine Research Office